Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Part of paid clinical trials in Duarte, California.

Sponsor: City of Hope Medical Center
Study ID: NCT00816283
Phase: PHASE1
Status: Completed

Conditions

Leukemia

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

dasatinib — DRUG
50 mg orally 2 times per day or 140 mg orally one time per day
vorinostat — DRUG
100 mg orally 2 times per day
cytogenetic analysis — GENETIC
Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
gene expression analysis — GENETIC
Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
mutation analysis — GENETIC
Performed at baseline and at every bone marrow analysis on peripheral blood
reverse transcriptase-polymerase chain reaction — GENETIC
Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
flow cytometry — OTHER
Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
laboratory biomarker analysis — OTHER
Performed pre-treatment and day +14 of treatment

Study Details

RATIONALE: Dasatinib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving dasatinib together with vorinostat may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of dasatinib when given together with vorinostat in treating patients with accelerated phase or blastic phase chronic myelogenous leukemia or acute lymphoblastic leukemia.